Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

Drug developers are pursuing a new option for reproductive care in the post-Roe landscape: birth control pills for men. Why ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million ...

Piramal's global Contract Development and Manufacturing Organization plans to more than double the facility’s capacity by Q1 ...

A new dark-money group called Americans for Pharma Reform has launched a multi-state bus tour to bring awareness to what they ...

(NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, and Intract Pharma Ltd. ("Intract"), a ...

As the efficiency and efficacy of injectable treatment options improve, more patients are expected to benefit from advanced therapies.

Mankind Pharma plans to raise up to Rs 10,000 crore through non-convertible debentures and commercial papers. The board ...

Mankind Pharma Ltd.’s board approved issuing Non-Convertible Debentures and Commercial Papers to raise up to ₹10,000 Crore, ...

The End the Vaccine Carveout Act, also called H.R. 9828, would get rid of liability shields for Big Pharma. “Although federal ...

Mankind Pharma will issue non-convertible debentures (NCDs) and commercial papers (CP) worth ₹5,000 crore. These funds will ...